A special section entitled “Menopause and Hormone Therapy” is being planned for publication in the April 2025 issue of The Journal of Pharmacology and Experimental Therapeutics. This special section will cover the most recent basic science and clinical research related to the physiology of menopause, menopause-associated disease risks, issues related to hormone therapy, disease prevention and healthy aging.
Currently, 1 billion women worldwide are postmenopausal, a number that will reach 1.65 billion by the year 2050. Menopause confers an increased risk for cardiovascular diseases including arterial hypertension and heart failure, chronic renal disease, reproductive tumors, obesity and diabetes, osteoporosis, depression, and dementia. Further efforts towards developing new preventive, diagnostic, therapeutic approaches for these unmet medical needs that represent a significant economic burden to society are required.
Articles that will be considered include, but are not limited to:
- Women's health
- Pharmacology and pharmacotherapy
- Physiology and pathophysiology
- Clinical medicine
- Cardiovascular medicine
- Endocrinology and metabolism
- Nephrology
- Neurology and psychiatry
- Gynecology
- Oncology
- Preclinical studies
- Novel and therapeutic approaches to menopause and menopause-related disease risks, during and after the menopausal transition
Especially welcome are full-length original research and mini-review articles on cardiometabolic diseases including arterial hypertension, obesity and diabetes; dementia, depression and cognitive impairment; and osteoporosis, frailty and aging. Journal editors highly encourage research papers describing innovative experimental models/mechanisms that test the efficacy and safety of hormone-based treatments. JPET will also consider short research reports on novel mechanisms, signaling pathways and therapeutic targets for understanding the (patho)physiology of menopause-associated symptoms and aging, and menopause-related disease risks. Expert opinion reports and mini-reviews on the latest advances in all of the above areas are also encouraged.
Article proposals, including title, author information, abstract and significance statement should be submitted as a presubmission inquiry to The Journal of Pharmacology and Experimental Therapeutics. These proposals will be reviewed by guest editors, Dr. Andrea Cignarella and/or Dr. Matthias Barton, who will respond to the authors with comments, and assess whether final approval will be granted for a full submission.
The submission deadline is July 31, 2024 and all submissions must refer to the journal’s Instructions to Authors. There are no submission fees or page charges for publishing in this special section, and accepted manuscripts will be published immediately online.